You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma

Article metrics

Article menu

Download PDFPDF

Oral Abstracts
Opening Ceremony and Plenary 1: Oral Abstract Presentations
O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to October 2024

AbstractFullPdf
Nov 2021109026
Dec 202193019
Jan 2022173028
Feb 2022109015
Mar 202275016
Apr 2022122023
May 202285017
Jun 202292018
Jul 20227407
Aug 202284016
Sep 2022134014
Oct 202265013
Nov 20227408
Dec 202248010
Jan 202381015
Feb 20237007
Mar 20236309
Apr 202381012
May 20236907
Jun 20235606
Jul 202365010
Aug 202310508
Sep 20238809
Oct 20238809
Nov 20236504
Dec 20237904
Jan 20247003
Feb 20242005
Mar 20242304
Apr 20242707
May 20243704
Jun 20242606
Jul 20243808
Aug 202457013
Sep 20242303
Oct 2024200
Total25700383